Proteome-wide covalent ligand discovery in native biological systems

Nature

Volumn 534, Issue 7608, 2016, Pages 570-574

  Backus, Keriann M ^a   Correia, Bruno E ^a   Lum, Kenneth M ^a   Forli, Stefano ^a   Horning, Benjamin D ^a   González Páez, Gonzalo E ^a   Chatterjee, Sandip ^a   Lanning, Bryan R ^a   Teijaro, John R ^a   Olson, Arthur J ^a   Wolan, Dennis W ^a   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 8; CYSTEINE; ELECTROPHILE; LIGAND; PROTEOME; SCAFFOLD PROTEIN; TRANSCRIPTION FACTOR; CASP10 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; ENZYME PRECURSOR; MOLECULAR LIBRARY; PEPTIDE FRAGMENT;

APOPTOSIS; BIOLOGICAL METHOD; CELLS AND CELL COMPONENTS; GENETIC ANALYSIS; LIGAND; PROTEIN; PROTEOMICS; QUANTITATIVE ANALYSIS;

APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; COVALENT BOND; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; CELL CULTURE; CHEMISTRY; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY; PROCEDURES;

APOPTOSIS; CASPASE 10; CASPASE 8; CELLS, CULTURED; CYSTEINE; DRUG EVALUATION, PRECLINICAL; ENZYME PRECURSORS; HUMANS; LIGANDS; PEPTIDE FRAGMENTS; PROTEOME; SMALL MOLECULE LIBRARIES; T-LYMPHOCYTES; TRANSCRIPTION FACTORS;

EID: 84975780780     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18002     Document Type: Article

References (43)

1. Edfeldt, F. N., Folmer, R. H. & Breeze, A. L. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today 16, 284-287 (2011).
2. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
3. Scott, D. E., Coyne, A. G., Hudson, S. A. & Abell, C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51, 4990-5003 (2012).
4. Erlanson, D. A. et al. Site-directed ligand discovery. Proc. Natl Acad. Sci. USA 97, 9367-9372 (2000).
5. Cardoso, R. et al. Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction. Protein Sci. 21, 1885-1896 (2012).
6. Nonoo, R. H., Armstrong, A. & Mann, D. J. Kinetic template-guided tethering of fragments. Chem Med Chem 7, 2082-2086 (2012).
7. Kathman, S. G., Xu, Z. & Statsyuk, A. V. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases. J. Med. Chem. 57, 4969-4974 (2014).
8. Jöst, C., Nitsche, C., Scholz, T., Roux, L. & Klein, C. D. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments. J. Med. Chem. 57, 7590-7599 (2014).
9. Miller, R. M., Paavilainen, V. O., Krishnan, S., Serafimova, I. M. & Taunton, J. Electrophilic fragment-based design of reversible covalent kinase inhibitors. J. Am. Chem. Soc. 135, 5298-5301 (2013).
10. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
11. Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316-329 (2016).
12. Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790-795 (2010).
13. Wang, C., Weerapana, E., Blewett, M. M. & Cravatt, B. F. A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles. Nature Methods 11, 79-85 (2014).
14. Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Edn Engl. 41, 2596-2599 (2002).
15. Liu, Q. et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146-159 (2013).
16. Lim, S. M. et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed. Engl. 53, 199-204 (2014).
17. Hoffstrom, B. G. et al. Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nature Chem. Biol. 6, 900-906 (2010).
18. Li, D. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702-4711 (2008).
19. Wissner, A. et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 46, 49-63 (2003).
20. Lanning, B. R. et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nature Chem. Biol. 10, 760-767 (2014).
21. London, N. et al. Covalent docking of large libraries for the discovery of chemical probes. Nature Chem. Biol. 10, 1066-1072 (2014).
22. DeLaBarre, B., Hurov, J., Cianchetta, G., Murray, S. & Dang, L. Action at a distance: allostery and the development of drugs to target cancer cell metabolism. Chem. Biol. 21, 1143-1161 (2014).
23. Held, J. M. et al. Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol. Cell. Proteomics 9, 1400-1410 (2010).
24. Vickers, C. J., González-Páez, G. E. & Wolan, D. W. Selective detection and inhibition of active caspase-3 in cells with optimized peptides. J. Am. Chem. Soc. 135, 12869-12876 (2013).
25. Krammer, P. H., Arnold, R. & Lavrik, I. N. Life and death in peripheral T cells. Nature Rev. Immunol. 7, 532-542 (2007).
26. Lafont, E. et al. Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor zVAD-fmk. PLoS ONE 5, e13638 (2010).
27. Wachmann, K. et al. Activation and specificity of human caspase-10. Biochemistry 49, 8307-8315 (2010).
28. Bidère, N., Su, H. C. & Lenardo, M. J. Genetic disorders of programmed cell death in the immune system. Annu. Rev. Immunol. 24, 321-352 (2006).
29. Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
30. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763 (2015).
31. Weerapana, E., Speers, A. E. & Cravatt, B. F. Tandem orthogonal proteolysisactivity-based protein profiling (TOP-ABPP)-a general method for mapping sites of probe modification in proteomes. Nature Protocols 2, 1414-1425 (2007).
32. Inloes, J. M. et al. The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. Proc. Natl Acad. Sci. USA 111, 14924-14929 (2014).
33. Adibekian, A. et al. Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat. Chem. Biol. 7, 469-478 (2011).
34. Consortium, T. U.; UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 43, D204-D212 (2015).
35. Law, V. et al. Drug Bank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2014).
36. Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235-242 (2000).
37. Camacho, C. et al. BLAST+ : architecture and applications. BMC Bioinformatics 10, 421 (2009).
38. DeLano, W. L. The PyMOL Molecular Graphics System (Delano Scientific, 2002).
39. O'Boyle, N. M. et al. Open Babel: an open chemical toolbox. J. Cheminform. 3, 33 (2011).
40. Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791 (2009).
41. Sanner, M. F., Olson, A. J. & Spehner, J. C. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 38, 305-320 (1996).
42. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9, 671-675 (2012).
43. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nature Methods 12, 7-8 (2015).